The pharmaceutical company reportedly offered 1,900 for its three-dose jab that can be administered to people over 12 years of age.
The world’s first DNA-based needle-free COVID-19 vaccine – ZyCov-D by Zydus Cadila. Image credit: Zydus
With talks underway between the central government and Zydus Cadila on the price of COVID-19[female[feminine vaccine, the pharmaceutical company has reportedly proposed 1,900 for its three-dose vaccine that can be administered to people over 12 years of age.
However, the government is negotiating a price cut and a final decision on this is expected to be made this week, sources familiar with developments said.
The government said on Thursday that the first locally developed DNA-based needle-free product COVID-19[female[feminine vaccine by Zydus Cadila will be introduced in the Coronavirus vaccination campaign soon.
“The company offered the price inclusive of all taxes. Negotiations are ongoing. The company was asked to reconsider all aspects regarding the cost of the vaccine. A final decision is expected to be made this week, ”a source said.
Another source said that the price of ZyCoV-D must be different from that of Covaxin and Covishield because, in addition to being a three-dose vaccine, there is a needleless jet injector used to deliver the vaccine which costs 30,000.
This jet injector can be used to deliver approximately 20,000 doses. The vaccine should be administered on days zero, 28 and 56.
According to sources, around three rounds of meetings have taken place between the Center and the company so far, the last Thursday.
The ministry is also awaiting recommendations from the National Immunization Technical Advisory Group (NTAGI) to introduce ZyCoV-D into the vaccination campaign and prioritize beneficiaries by focusing on people aged 12 to 18 with co-morbidities.
NTAGI will provide the protocol and framework for its introduction into the vaccination campaign, an official source said.
Regarding the price at which it will be purchased, Union Health Secretary Rajesh Bhushan, at a press conference on Thursday, said the government was in conversation with manufacturers.
“As this is a three-dose vaccine and comes with a needle-free delivery system, it would be priced differently than existing vaccines,” he said.
The ZyCoV-D vaccine received emergency use authorization from the drug’s regulator on August 20, making it the first vaccine to be given to the 12 to 18-year-old group in addition to adults.
Covishield, Covaxin, and Sputnik V are only given to people over the age of 18 and unlike ZyCoV-D, they are two-dose vaccines.